| 0.295 0.011 (3.87%) | 04-23 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.36 | 1-year : | 0.4 |
| Resists | First : | 0.3 | Second : | 0.34 |
| Pivot price | 0.28 |
|||
| Supports | First : | 0.24 | Second : | 0.2 |
| MAs | MA(5) : | 0.29 |
MA(20) : | 0.29  |
| MA(100) : | 0.35 |
MA(250) : | 1.51 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 46.2 |
D(3) : | 47.6 |
| RSI | RSI(14): 47.2 |
|||
| 52-week | High : | 12 | Low : | 0.23 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ AZTR ] has closed below upper band by 37.0%. Bollinger Bands are 65.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 7 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.31 - 0.31 | 0.31 - 0.31 |
| Low: | 0.28 - 0.28 | 0.28 - 0.28 |
| Close: | 0.29 - 0.3 | 0.3 - 0.3 |
Azitra, Inc., a pre-clinical biopharmaceutical company, focuses on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It is developing ATR-12, a genetically modified strain of S. epidermidis for treating Netherton syndrome, a skin disease; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. The company was incorporated in 2014 and is based in Branford, Connecticut.
Wed, 26 Feb 2025
Maxim Group cuts Azitra stock price target to $2 from $3, retains Buy rating - Investing.com
Thu, 06 Feb 2025
Azitra Inc. issues new warrants in connection with stock sale - Investing.com
Tue, 04 Feb 2025
Azitra secures $930K in registered direct offering - Investing.com
Tue, 04 Feb 2025
Struggling Biotech Azitra Raises Emergency Capital: Inside the $930K Deal - Stock Titan
Tue, 04 Feb 2025
Azitra Announces Pricing of $930.0 Thousand Registered Direct Offering of Common Stock - PR Newswire
Mon, 03 Feb 2025
Azitra, Inc. to Present at the BIO CEO & Investor Conference – Company Announcement - Financial Times
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
AMEX
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 8 (M) |
| Held by Insiders | 6.83e+006 (%) |
| Held by Institutions | 10.6 (%) |
| Shares Short | 311 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.012e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -35 % |
| Return on Assets (ttm) | 470.3 % |
| Return on Equity (ttm) | -93.5 % |
| Qtrly Rev. Growth | 408200 % |
| Gross Profit (p.s.) | 0.02 |
| Sales Per Share | 0.05 |
| EBITDA (p.s.) | -0.63 |
| Qtrly Earnings Growth | 92.3 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -9 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 5.69 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 208380 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|